BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28
• 31

• Press Releases

  Shanton Reveals Topline Data from Phase 2b Study in Refractory Gout Patients

  March 28, 2025

   · 

  4 min read
• Press Releases

  DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

  March 28, 2025

   · 

  32 min read
• Press Releases

  Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

  March 28, 2025

   · 

  22 min read
• Press Releases

  Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint

  March 28, 2025

   · 

  3 min read
• Press Releases

  Pharming Group to participate in April 2024 investor conferences

  March 28, 2025

   · 

  1 min read
• Press Releases

  Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release

  March 28, 2025

   · 

  2 min read
• Press Releases

  Zymewire Releases 2024 Industry Report, Equipping Service Provider Sales Teams with Practical Biopharma Insights

  March 28, 2025

   · 

  1 min read
• 

  Cancer

  Merck’s Injectable Keytruda Matches IV Formula in Pivotal Trial

  Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s patent cliff at bay.

  March 28, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  Cancer

  BioNTech’s Bispecific Elicits Treatment Response in Majority of SCLC Patients

  BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

  March 28, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

  March 28, 2025

   · 

  4 min read